DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck
Addition of concomitant zalutumumab to primary (chemo-)radiotherapy and concomitant nimorazole for HNSCC did not increase loco-regional control nor disease-specific or overall survival.
Authors
- Hanne Primdahl (ORCID: https://orcid.org/0000-0003-3562-0026)
- Jesper Grau Eriksen (ORCID: https://orcid.org/0000-0002-1145-6033)
- Claus Andrup Kristensen (ORCID: https://orcid.org/0000-0002-6250-0161)
- Jens Overgaard (ORCID: https://orcid.org/0000-0002-0814-8179)
- Christian Maare (ORCID: https://orcid.org/0000-0002-9698-2082)
- Åse Bratland
- Jan Alsner (ORCID: https://orcid.org/0000-0002-5395-3193)
- Jørgen Johansen (ORCID: https://orcid.org/0000-0003-3911-3929)
- Maria Andersen (ORCID: https://orcid.org/0000-0002-6598-9740)
Institutions
- Oslo University Hospital (NO)
- Aalborg University Hospital (DK)
- Norwegian Cancer Society (NO)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1016/j.radonc.2025.110899
- Citations
- 4
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 7.39
Funders
- Kræftens Bekæmpelse